Lightnews — Scholar-powered news

Endpoints News @endpts.com · 6m

Are the good times in biotech back? Tune in to Post-Hoc Live with @drewsnews.bsky.social, Tim Opler and John Carroll on XBI, M&A, pricing pressure and IPOs. Join us at 12:30 pm ET.

Are the good times in biotech … back? Live today at 12:30 pm E.T.

Biotech market shows signs of recovery with XBI price rise, as Stifel's Tim Opler and John Carroll join Post-Hoc Live to discuss market trends and dealmaking at 12:30 ET.

endpoints.news

2

Endpoints News @endpts.com · 16m

Which big pharma is striking the most deals? New data reveal the leaders in licensing activity — and what’s driving their deal streaks.

Which big pharma has the busiest BD team? You might be surprised

Eli Lilly leads in licensing deals since 2024, with Novartis topping total deal value at $42.5B. Phase 1 deals see spike in upfront payments, reaching $350M median in 2025.

endpoints.news

Endpoints News @endpts.com · 19h

Lila Sciences closed a $350M Series A to advance its “AI-doing-science” vision — connecting models to experiments to create scientific superintelligence.

Lila Sciences closes $350M Series A for its AI-doing-science vision

Lila Sciences' $350 million Series A round is a $115 million boost from what it announced in September.

endpoints.news

1

Endpoints News @endpts.com · 21h

How does Outcomes AI plan on using $10M seed funding to cut down nursing costs? By having AI voice agents handle routine scheduling and follow-up interactions and supporting human nurses with AI-powered admin tools.

Exclusive: Ex-Biofourmis CEO raises $10M for new startup

OutcomesAI raised $10 million in seed funding to cut down on nursing costs, Endpoints News learned exclusively. The Boston-based startup is made of two parts: AI voice agents that handle ...

endpoints.news

Endpoints News @endpts.com · 22h

Q&A: Medicine Nobel prize winner Fred Ramsdell discovered his curiosity of how things worked in high school, and fell in love with science in college. He spoke to Lei Lei Wu from snowy Montana about becoming a Nobel honoree, cell therapy, and basic science research.

Q&A with Nobel winner Fred Ramsdell on basic research in biotech, and the future of cell therapy

Fred Ramsdell, who won the Nobel Prize in Physiology or Medicine with Mary Brunkow and Shimon Sakaguchi, spoke with Endpoints on Monday about the 'surreal' honor, cell therapy for autoimmune diseases,...

endpoints.news

1 2

Endpoints News @endpts.com · 1d

Kailera has raised $600 million to begin late-stage obesity trials this year, making it the largest biotech fundraising deal of the year.
endpoints.news/obesity-biot...

Obesity biotech Kailera gets $600M to start Phase 3 this year

Kailera Therapeutics raises $600M Series B to advance obesity drugs, including Phase 3 trials of GLP-1/GIP receptor agonist KAI-9531 licensed from Hengrui Pharma.

endpoints.news

Endpoints News @endpts.com · 1d

Bristol Myers and insitro have extended their research deal to find a new drug to treat ALS, Endpoints News has learned exclusively.
endpoints.news/bristol-myer...

Exclusive: Bristol Myers, insitro extend research deal to find a drug for new ALS target

Bristol Myers will pay up to $20 million to extend its research collaboration with insitro by a year, the companies exclusively told Endpoints News.

endpoints.news

1

Endpoints News @endpts.com · 1d

Excellergy has high ambitions to treat allergies and inflammation. Its experimental drugs, "effector cell response inhibitors”— ECRIs, for short—could treat anything from food allergies to eczema. endpoints.news/excellergy-d...

A fresh biotech has a radical plan to treat inflammation and allergies, setting its sights on Xolair

Startup Excellergy debuts with $70M Series A to develop drugs targeting allergic diseases, aiming to compete with Roche/Novartis' Xolair through new immune response approach.

endpoints.news

1

Endpoints News @endpts.com · 1d

Tvardi's shares $TVRD crashed this morning after the company reported a mid-stage trial failure for its STAT3 candidate.

Tvardi's stock crashes as STAT3 drug fails in Phase 2 after extensive dropouts from side effects

Tvardi Therapeutics said TTI-101 did not show a difference from placebo in an 88-patient study for idiopathic pulmonary fibrosis; shares fell more than 85%.

endpoints.news

Endpoints News @endpts.com · 2d

Novo Nordisk has shut down its research into cell therapies as part of its ongoing restructure.
endpoints.news/novo-nordisk...

Novo Nordisk quits cell therapy as restructure continues

Novo Nordisk discontinues cell therapy R&D unit affecting ~250 employees, culling programs for heart failure, Parkinson's and diabetes, as CEO Doustdar reshapes company

endpoints.news

1

Endpoints News @endpts.com · 2d

Is the worst over in biopharma? Founding editor John Carroll has analysed the trend across the third quarter, and there are some encouraging signs.
endpoints.news/biopharma-de...

Is the worst over? Biopharma dealmaking shows an uptick in third quarter

Biotech market shows Q3 recovery with XBI breaking $100, increased M&A activity led by Merck's $10B Verona buyout, and China's rise to 38% of global deals in 2025.

endpoints.news

1

Endpoints News @endpts.com · 4d

The Biosecure Act is back — but this version drops direct mentions of WuXi, easing biotech fears while keeping the door open for future scrutiny.

Biosecure is back. It doesn't appear as threatening to biotechs as before

The Biosecure Act has another chance in Congress after the Senate passed a new version this week. But the latest iteration stops short of targeting WuXi AppTec and WuXi Biologics, key fixtures in US d...

endpoints.news

Endpoints News @endpts.com · 4d

AstraZeneca expected to announce MFN deal with White House Friday evening

White House, AstraZeneca expected to announce drug price deal: MSNBC

White House and AstraZeneca expected to announce drug pricing deal Friday, following Pfizer's agreement last week with Trump administration on price discounts.

endpoints.news

Endpoints News @endpts.com · 4d

Bristol Myers has entered the in vivo CAR-T race: the giant has announced it'll acquire Orbital Therapeutics for $1.5B cash.

Bristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition

Bristol Myers Squibb acquires Orbital Therapeutics for $1.5B cash to expand in vivo CAR-T therapy development, focusing on autoimmune diseases with OTX-201 program.

endpoints.news

1 2

Endpoints News @endpts.com · 5d

Samsara BioCapital has backed dozens of companies in life sciences, and it's now trying to raise a $200M opportunity fund.
endpoints.news/samsara-bioc...

Samsara BioCapital eyes $200M opportunity fund

Samsara BioCapital seeks to raise $200M for opportunity fund, having secured $98M from 19 investors. Firm has made 180+ investments since 2017, including Abcuro and Dewpoint.

endpoints.news

1 2

Endpoints News @endpts.com · 5d

This week's Peer Review has landed: Former CSO at Shape moves to Moderna as CTO; Eli Lilly scoops up former FDA official Peter Marks; and there are a flurry of changes happing at the FDA. Get the full rundown: endpoints.news/shapes-inter...

Shape's former CSO picks up tech role at Moderna; Lilly reels in Peter Marks

Former Shape Therapeutics CSO David Huss joins Moderna as CTO of research unit. Previously served as Shape's interim CEO before departing the Seattle biotech this summer.

endpoints.news

1

Endpoints News @endpts.com · 5d

In China, biotech startups like Lantu Biopharma are racing to make low-cost gene therapies for spinal muscular atrophy, challenging Zolgensma’s $2M price tag and global reach.

In China, a low-cost push to rival a life-saving, $2M medicine

Indian veterinarian Nirnay Murthy sought Lantu Biopharma's experimental gene therapy for his son's spinal muscular atrophy after being unable to afford Novartis's $2.1M Zolgensma treatment.

endpoints.news

1

Endpoints News @endpts.com · 5d

Former Moderna execs Lorence Kim and Evan Rachlin launched Ascenta Capital with $325M, focusing on biotechs in early human trials.

Former Moderna leaders raise $325M for biotech venture firm Ascenta Capital

Former Moderna execs Lorence Kim and Evan Rachlin launch Ascenta Capital with $325M fund, focusing on biotech investments with six deals already completed.

endpoints.news

1

Endpoints News @endpts.com · 6d

Novo Nordisk spending $4.7B to buy MASH specialist Akero.
endpoints.news/novo-nordisk...

Novo Nordisk to buy MASH player Akero for $4.7B upfront

Novo Nordisk to acquire Akero Therapeutics for $4.7B upfront, gaining efruxifermin for MASH treatment. Deal could reach $5.2B with contingent value right.

endpoints.news

Endpoints News @endpts.com · 6d

Expedition Therapeutics raising $165M for Chinese COPD drug.
endpoints.news/akero-ceo-is...

Akero CEO is named chair of Expedition, which raised $165M for COPD drug from China

Akero CEO Andrew Cheng named board chair at Expedition Therapeutics as company raises $165M, licenses COPD drug from Fosun Pharma with CEO Yi Larson at helm

endpoints.news

Endpoints News @endpts.com · 6d

Lawyers are scrambling to interpret Trump’s threatened 100% pharma tariffs, as biopharma clients seek clarity on timing, scope, and construction rules.

Lawyers scramble on how to advise clients on Trump’s 100% pharma tariff threat

Lawyers told Endpoints News that companies are struggling to understand the intricacies of Trump’s tariff warning, with confusion over how the White House is defining starting construction on factorie...

endpoints.news

1

Endpoints News @endpts.com · 6d

In Focus: Amgen’s David Reese traded his R&D role to lead its AI revolution. He calls it biotech’s ‘hinge moment’ — and Endpoints’ Andrew Dunn got an inside look.

David Reese bets his career on the 'hinge moment' for AI at Amgen

Dave Reese left Amgen R&D head role to become CTO, leading AI transformation. Working with CEO Bob Bradway, he's reorganizing company to integrate AI across drug development processes.

endpoints.news

Endpoints News @endpts.com · 7d

Former FDA biologics chief Peter Marks is joining Eli Lilly as SVP for molecule discovery and head of infectious diseases, months after his CBER exit.
endpoints.news/lilly-hires-...

Lilly hires ex-CBER chief Marks, who is focusing on molecule discovery and infectious diseases

Peter Marks, former FDA official who led CBER, joins Eli Lilly as SVP for molecule discovery and head of infectious diseases after resigning from FDA in March.

endpoints.news

Endpoints News @endpts.com · 7d

Sanofi and Orano Med’s radiopharma AlphaMedix met both primary endpoints in Phase 2 for a rare type of cancer, suggesting tumor shrinkage and prolonged benefits.
endpoints.news/sanofi-and-r...

Sanofi and radioligand partner Orano Med report mid-stage win in rare tumor

Sanofi and Orano Med's AlphaMedix succeeds in Phase 2 trial for gastroenteropancreatic neuroendocrine tumors, demonstrating meaningful response rates at two years.

endpoints.news

Endpoints News @endpts.com · 7d

Soufflé Therapeutics, co-founded by Bob Langer, launched with $200M to develop targeted genetic medicines for muscle, heart, and metabolic diseases.

Soufflé Therapeutics, co-founded by Bob Langer, launches with $200M

Moderna co-founder Bob Langer's Soufflé Therapeutics emerges from stealth with $200M Series A, targeting muscle and heart diseases including FSHD with nucleic acid therapies.

endpoints.news

3 6